



## Dr Raja T

MBBS, MD, DM 20+ Years Experience

Dr Raja T is a top Medical Oncologist in Chennai at Apollo Hospitals Greams Road Chennai, Apollo Cancer Institutes, Apollo Proton Cancer Centre . Book appointment online with Dr Raja T at Ask Apollo.

### Hospitals

Apollo Hospitals, Greams Road, Chennai ,

Doctor's Working  
Weekdays  
Mon - Sat

Doctor's Working  
Hours  
08:00 -09:00

Phone Icon  
Call Now

Calendar Icon  
Book Appointment

## Overview

Dr. Raja T is a highly qualified oncologist based in Chennai, Tamil Nadu, with over 20 years of dedicated experience in the field of oncology. He holds prestigious qualifications including MBBS, MD, and DM, showcasing his extensive training and expertise in cancer treatment and management. Dr. Raja is committed to providing comprehensive care to his patients, utilizing the latest advancements in medical technology and treatment methodologies to ensure the best possible outcomes. Fluent in English, he effectively communicates with a diverse patient population, ensuring that each individual understands their condition and treatment options. As a part of the esteemed Apollo network, Dr. Raja T is known for his patient-centric approach, which prioritizes empathy, education, and support throughout the cancer care journey. He is recognized for his thorough assessments and personalized treatment plans, aiming to empower his patients at every step. Dr. Raja's clinical acumen and dedication to his field make him a trusted oncologist for those seeking expert care in Chennai.

## Experience

DNB Medical Oncology Teacher. (Sub Speciality Teaching Program) in Apollo Speciality Hospital, Tamil Nadu, Chennai, India- From 2014 to till date

Senior Consultant in Medical

Oncology & Senior Consultant in BMT in Apollo Speciality Hospital, Tamil Nadu, Chennai, India- From 1999 to till date

Member of the Inspection Commission in University of Madras, Tamil Nadu, Chennai, India- 2011

DNB Medical Oncology Teacher in V.S. Hospital, Tamil Nadu, Chennai, India- 2009

Adjunct Associate Professor University of Queensland, School of Medicine, Brisbane- 2009

Junior Consultant in Medical

Oncology and BMT Apollo Speciality Hospital,

Tamil Nadu, Chennai, India- From 1997 Sep to 1999 Jan

Senior Registrar in Apollo Speciality Hospital, Tamil Nadu, Chennai, India- From 1996 to 1997 Sep

Honorary Observer in BMT The Royal Free Hospitals, London- From 1998 to 1998 Jul

- April 2015 to till date Breast Cancer Registry to Collate Data on Epidemiology and Treatment Patterns & Outcomes of Breast Cancer in India
- 2012 A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma.
- From 2012 to till date A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients with HER2-positive and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer
- From 2012 to till date A Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma
- From 2012 to till date A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial To Evaluate The Efficacy Of T-Dm1 Compared With Treatment Of Physician's Choice In Patients With Her2-Positive Metastatic Breast Cancer Who Have Received At Least Two Prior Regimens Of Her2-Directed Therapy
- From 2012 to till date A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma

- From 2012 to till date Principal Investigator for An Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd)
- From 2009 to till date Principal Investigator in a phase II biomarker identification trial for Erlotinib (Tarceva®) in patients with advanced pancreatic carcinoma (MARK)
- From 2009 to till date Principal Investigator for A Randomized, Double – blind, Multicenter, Phase III study of Brivanib versus Sorafenib as first – line treatment in patients with advanced Hepatocellular Carcinoma (HCC) The BRISK FL Study
- From 2007 to till date -Principal Investigator a Phase III, randomized, double blind, multicenter, placebo-controlled study of adjuvant Lapatinib in women with early Stage Erb2 over expressing breast cancer.

### **Experience In Clinical Trials:**

From 2011 to 2011 Principal Investigator for A Open Label, Non –Controlled, on Randomized, Interventional Pilot study to evaluate the response rate after Induction therapy with Docetaxel (T) and Cisplatin (P) in Unrespectable locally Advanced Squamous Cell Carcinoma of Head and Neck.

From 2011 to Dec 2011 Principal Investigator for A randomized, open label, active controlled, comparative parallel group and multicentric study :Efficacy and safety of Paclitaxel Nano Dispersion Concentrate for injection (PICN) in subjects with metastatic breast cancer

From 2011 to 2011 Principal Investigator for A Multicentric open label Phase III study to evaluate the safety and efficacy of Rituximab (Zenotech) in Non Hodgkin's Lymphoma.

From 2009 to Feb 2012 Principal Investigator for a A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have failed or are Intolerant to Sorafenib (BRISK-PS)

From 2008 to Nov 2011 - Principal Investigator in a phase 2, multicenter, open label, randomized trial of AMG 706 or Bevacizumab in combination

2009 - Principal Investigator in a randomized, multi-centre, open label study to evaluate safety and efficacy of PEG G-CSF as compared to Grafeel® in the Prophylaxis of severe Neutropenia in cancer patients receiving cytotoxic chemotherapy

- 2008 - Principal Investigator in a randomized, double-blind Phase III study of Gemcitabine + against 013736 versus Gemcitabine + placebo in first line treatment with patients with locally advanced, resectable or metastatic pancreatic cancer
- 2007 to 2008 - Principal Investigator in a Phase III, randomized, open labelled, multicentre study of XRP6258 at 25mg/m<sup>2</sup> in combination with prednisone for the treatment of hormone refractory metastatic prostate cancer previously treated with Taxotore® containing regimen with Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer.

2006 to 2008 - Principal Investigator in prospective, non-comparative, open-label, multicentre study to evaluate safety and efficacy of Pegfilgrastim (IPL-PO5) for prevention of Neutropenia in the patients receiving chemotherapy.

2006 Apr to 2010-Principal Investigator in Phase III trial on Pixantrone for third line single treatment of patients with relapsed aggressive Non – Hodgkins Lymphoma

2006 Apr to 2010- Principal Investigator in Phase III trial on Glufosfamide compared with best supportive care in metastatic pancreatic Adenocarcinoma previously treated with Gemcitabine.

Principal Investigator in Phase III trial on Glufosfamide compared with best supportive care in metastatic pancreatic Adenocarcinoma previously treated with Gemcitabine

2005 Mar to 2006 - Principal Investigator in Phase III, randomized, double - blind, comparative study of Micafungin (FK 463) Versus Caspofungin as antifungal treatment in patient with Invasive Candidiasis or Candidemia.

2003 Oct to 2004 – Principal Investigator in Phase III trial on Multicentre double blind comparative randomised study to evaluate the efficacy and safety of Micafunginvs liposomal Amphotericin B (Ambisome) in the treatment of invasive Candidiasis And Candidemia.

2003 Aug to Dec 2004-Principal Investigator in open labelled observational PMS study using Octreotide long acting in patients of inoperable Hepatocellular Carcinoma.

2003 Jan to Dec 2004- Principal Investigator in observational PMS study on ZOMETA in patients with prostate cancer, breast cancer & Multiple Myeloma.

2003 Oct to Dec 2004- Principal Investigator in Phase II trial on ALIMTA in patients with advanced non small cell lung cancer who have had prior chemotherapy.

1999 Sep to Dec 2000-Co-Investigator in multicentric, multinational phase II - trial on head and Neck Squamous Cell Carcinoma with Gemcitabine plus Cisplatin chemotherapy.

## Membership

- ESMO Asia CME Partner Centers – Colorectal Cancer Program
- Indian society of medical and pediatric oncology(ISMPO)
- Indian society of oncology (ISO)
- Association of physicians of India(IAP)
- European society of Bone marrow transplants(EBMT)
- Elected as a member 2009, for the executive committee ISO
- Member ICON : Indian Cooperative Oncology Network

# Awards

- Conferred “**Best Doctor Award**” by *The Tamil Nadu Dr. MGR Medical University* on 1st July 2012
- **Gold Medalist** at Gujarat University, India in 1996 for DM Oncolog

# Research and Publication

Chapter 19 – Principles of Cancer Management

Text book of Medicine to be release, Jaypee Brothers

48-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy

E cancer medical science; volume 8:406 25th February 2014

Repurposing old drugs and metronomic therapy

Oncology Gold Standard BCU 2014

Optimizing Second line therapy for Chronic Myeloid Leukemia (CML)

Indian Journal of Cancer; Volume 49; Issue 1; January –March 2012; Page 46-56

Diffuse Infiltrating Retinoblastoma with Central Nervous System Metastasis,

Archives 2011 (Ophthalmology) Vol:129, and No: 3, March 2011, American Medical Association.

Recognition and management of childhood acute lymphoblastic Leukemia in peripheral hospitals.

Indian Journal Of Practical Pediatrics October – December-1997: 323 Vol.5, No:4

Amifostine, for drug review.

IND. J. MED. & PED. ONCOL. 1995, Vol:16: 68-69

Chemotherapy of gastrointestinal malignancies.

IND. J. MED. & PED. ONCOL. 1995, Vol:16: 93-98

Priapism in a child with pelvic Rhabdomyosarcoma, a case report and Review of literature.

IND. J. MED. & PED. ONCOL. 1995, Vol:16: 188-191

## Presentation In International Conference:

- Program Director for ESMO Asia CME Partner Centers – Colorectal Cancer Program, 23 April 2012
- Invited speaker on Ca Lung and Renal Cell Carcinoma for the Malaysian society of Hematology annual meeting, in Hanoi, Vietnam 2009.

- Invited as a member of the Asian NCCN Renal cell carcinoma Guidelines meeting, in Beijing, China, 2008.
- Invited speaker for the Malaysian society of Hematology Annual Meeting , in Bangalore, India, 2007
- Invited speaker for the Asia pacific regional oncology forum in Bangkok, Thailand, 2006
- Invited speaker on European society of medical oncology, expanding Horizons program - Bombay, February 2003.
- Cord blood transplantation coauthor-on Eurocord Abstract American society of hematology, annual meeting, in Orlando 2001.
- Invited as a young investigator in young investigators meeting, 2000, Indianapolis U.S.A-global Lilly young investigators meet (GLYIM)
- First SIOP workshop for trainers in pediatric oncology, Bombay, Mar.'97 selected as one of the national trainers
- Presented a paper on stem cell in children in a developing country combined annual meet of SIOP & ASPH/o, transplants Montreal,

#### **Papers Presented In National Conferences:**

ISO meeting at Amrita Institute Cochin, Invited Speaker July 2012

Invited faculty as the chairperson and modulator (MBC session) of Asian Breast Cancer Congress 2012

Invited faculty as speaker at the ESMO, Asia conference in New Delhi

Invited faculty asspeaker at the AIIMS in New Delhi

Invited faculty as speaker at the BEST of ASCO conference in New Delhi, 2011

Invited faculty as speaker at the BEST of ASCO conference in New Delhi, 2009

Invited faculty as speaker at the BEST of ASCO conference in New Delhi, 2008

Invited speaker on cord blood transplants - 39th national conference of Indian society of hematology & blood transfusion, Chennai, India, Nov 98

Invited speaker on Stem cell transplantation, the experience at the Apollo cancer hospitals chennai-39th national conference of Indian society of hematology & blood transfusion, Chennai, Nov 1998

Presented paper on Bone marrow & stem cell transplantation, the experience Apollo cancer hospitals, Chennai - 9th biennial conference of the Indian At The Society Of Medical & Pediatric Oncology Feb. 1997

Presented paper on comparison of CHOP VS CNOP for Adult Non Hodgkin's Lymphoma- 8th biennial conference of the Indian society of Medical & Pediatric - Oncology, Feb. 1995

Presented paper on comparison of platinum plus 5fu & methotrexate plus 5fu in Locally Advanced Head And Neck Squamous Cell Carcinomas-8th Biennial Conference Of The Indian Society of medical and pediatric oncology, Feb. 1995

# Frequently Asked Questions

## 1. Where does Dr. Raja T practice?

Dr. Raja T currently practices at Apollo Hospitals, Greams Road, located in Chennai.

## 2. Who is Dr. Raja T?

Dr. Raja T is a highly experienced Medical Oncologist with 20 years of expertise in the field. He is known for providing exceptional patient care and advanced medical treatments. His areas of expertise include Gynecological Cancer Treatment, Brain Cancer Treatment. He also treats conditions such as , Angiosarcoma.

## 3. Why do patients choose Dr. Raja T?

Patients trust Dr. Raja T for his expertise, patient-centric approach, and commitment to providing the highest standard of care. He is well-versed in the latest medical advancements and ensures personalized treatment for every patient.

## 4. What is Dr. Raja T's specialization?

Dr. Raja T specializes in Medical Oncology, with expertise in treatments for Gynecological Cancer Treatment, Brain Cancer Treatment.

## 5. What are Dr. Raja T's medical qualifications?

Dr. Raja T holds prestigious qualifications, including MBBS, MD, DM.

## 6. How many years of experience does Dr. Raja T have?

Dr. Raja T has 20 years of experience in the medical field, treating various conditions related to Medical Oncology.

## 7. How can I book an appointment with Dr. Raja T?

You can book an appointment with Dr. Raja T through: Online: Visit <https://www.apollohospitals.com/book-doctor-appointment/> to schedule an appointment.